Colorectal cancer (CRC) is one of the most common malignancies. Unfortunately a significant proportion of surgically cured patients in the early stage of the disease develop progression and die from the disease. DNA microarrays technology was used in more than sixty studies focused on colorectal cancer during last five years.
High-density DNA microarrays showed good analytical ability also in colorectal cancer prognosis. However, comparability and reproducibility of studies based on high-density DNA microarrays are notably affected by their technological diversity, and recent findings are not conclusive .
This study aimed to find individual up/down-regulated genes associated with progression and metastatic potential of colorectal cancers using low-density oligonucleotide microarrays spotted with genes known to be involved in process of metastasis development. We suppose that focusing on a particular biological pathway may be more useful than genome-wide screening for our purposes.
Molecular characterization of patients at high risk of cancer progression using this more economical and productive expression profiling method may improve our knowledge about cancer progression and dissemination and also assist to oncologists in treatment decision by selecting those patients who will need adjuvant chemotherapy.
Filed under: bioinformatics, clinical diagnostics, Clinical microarrays, cost efective custom array, custom microarray, drug development, drug discoverry, gene expression, genetics, genotyping, microarray, microarray for clinical diagnostics |